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Abstract
We present here an extensive study of differential gene
expression in the initiation, acute and chronic phases of murine
autoimmune arthritis with the use of high-density oligonucleotide
arrays interrogating the entire mouse genome. Arthritis was
induced in severe combined immunodeficient mice by using
adoptive transfer of lymphocytes from proteoglycan-immunized
arthritic BALB/c mice. In this unique system only proteoglycan-
specific lymphocytes are transferred from arthritic mice into
syngeneic immunodeficient recipients that lack adaptive
immunity but have intact innate immunity on an identical (BALB/
c) genetic background.
Differential gene expression in response to donor lymphocytes
that migrated into the joint can therefore be monitored in a
precisely timed manner, even before the onset of inflammation.
The initiation phase of adoptively transferred disease (several
days before the onset of joint swelling) was characterized by
differential expression of 37 genes, mostly related to
chemokines, interferon-γ and tumor necrosis factor-α signaling,
and T cell functions. These were designated early arthritis
'signature' genes because they could distinguish between the
naive and the pre-arthritic state. Acute joint inflammation was
characterized by at least twofold overexpression of 256 genes
and the downregulation of 21 genes, whereas in chronic arthritis
a total of 418 genes with an equal proportion of upregulated and
downregulated transcripts were expressed differentially.
Hierarchical clustering and functional classification of
inflammation-related and arthritis-related genes indicated that
the most common biological activities were represented by
genes encoding interleukins, chemokine receptors and ligands,
and by those involved in antigen recognition and processing.
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Introduction
The completion of the human and mouse genome sequenc-
ing programs and the subsequent annotation of previously
unidentified genes have opened a new epoch in biology
and biomedical sciences. The genetic information greatly
facilitated the discovery of novel disease-related genes and
the mapping of signature genes for early diagnosis. More
specifically, polynucleotide or oligonucleotide arrays have
been applied in both human and experimentally induced
disease conditions to determine characteristic expression
patterns of signature genes.
In an inflammatory disease such as rheumatoid arthritis
(RA), the gene expression profile is extremely complex
owing to the diversity of cell types involved in the pathology
and the polygenic character of the autoimmune disease [1-
5]. The overall picture of molecular interactions in an
inflamed joint, deduced from gene expression studies in
both RA and its corresponding animal models, involves pro-
teins participating in immunity, inflammation, apoptosis,
proliferation, cellular transformation and cell differentiation,
and other processes [3-8]. Several studies analyzed the
patterns of gene expression in peripheral blood or synovial
fluid mononuclear cells, and in the inflamed synovium of
AA = acutely arthritic; AN = absolutely negative (control naive); CA = chronically arthritic; CV = coefficient of variation; DDA = dimethyldioctadecy-
lammonium bromide; PA = pre-arthritic; PG = cartilage proteoglycan aggrecan; PGIA = PG-induced arthritis; RA = rheumatoid arthritis; SCID = 
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human patients [1,3-5,7,9-11]. However, the genetic heter-
ogeneity of the human population is a serious obstacle to
the correct interpretation of data in gene expression stud-
ies. Animal models of RA can facilitate the interpretation of
genome-wide gene expression by providing genetic and
clinical homogeneity, and an opportunity to monitor the
onset and progression of the disease [12-20]. DNA micro-
array technology was successfully applied to inflamed
paws of mice or rats systemically immunized with arthri-
togenic compounds to induce arthritis [6,21-23]. Despite
the usefulness of the information provided by these studies,
the early gene expression events at the site of inflammation
(joint and synovium) and the mechanisms of disease initia-
tion remain unknown.
Systemic immunization of genetically susceptible BALB/c
mice with human cartilage proteoglycan aggrecan (PG)
induces PG-specific immune responses that then trigger
inflammation in peripheral joints [13,19]. PG-induced
arthritis (PGIA) is a murine model which bears many simi-
larities to RA as indicated by clinical assessments, radio-
graphic analyses, various laboratory and functional tests,
and by histopathologic studies of diarthrodial joints
[13,19,24,25]. Moreover, genome-wide screening studies
identified multiple genomic loci in PGIA [20,26-29] that are
syntenic with those described in RA [25]. Both RA and
PGIA are polygenic autoimmune diseases with a major per-
missive role of the MHC, although non-MHC genes
account for a significant portion of the genetic susceptibil-
ity. PGIA can be successfully transferred into naive BALB/
c or syngeneic severe combined immunodeficient (SCID)
mice either with unseparated spleen cells or with antigen
(PG)-stimulated T lymphocytes from arthritic donor BALB/
c mice [30-32].
In the present study, we adoptively transferred the disease
(PGIA) into syngeneic BALB/cSCID mice lacking functional
T and B cells. SCID mice carry a natural mutation that pre-
vents the V(D)J recombination in B and T lymphocytes,
resulting in a failure to generate functional immunoglobulins
and T cell receptors [33,34]. Consequently, adoptively
transferred arthritis in BALB/cSCID mice is an ideal model in
which activated lymphocytes of arthritic donor BALB/c
mice migrate and interact with the intact innate immunity
environment in the joints of BALB/cSCID mice. The gene
expression profiles in normal, pre-arthritic and arthritic
joints of the recipient BALB/cSCID mice were determined by
using DNA microarray technology (Affymetrix). Although a
significant number of genes were differentially expressed in
joints with acute and chronic arthritis, in this study we
focused on early genes whose expression occurred before
the onset of clinical symptoms.
Methods
Animals, antigen and immunization
The use of human cartilage from joint replacement surger-
ies for antigen isolation was approved by the Institutional
Review Board, and all animal experiments were approved
by the Institutional Animal Care and Use Committee.
Female BALB/c mice at the age of 24–26 weeks (National
Cancer Institute, Kingston Colony, New York, USA) were
injected intraperitoneally with 100 µg of cartilage PG
(measured as protein) emulsified in dimethyldioctadecy-
lammonium bromide (DDA) adjuvant (Sigma-Aldrich, St
Louis, Missouri, USA). The use of adjuvant DDA allowed us
to avoid the harmful effects of oil and bacterial proteins
present in Freund's adjuvants [35,36]. Booster injections of
the same doses of PG with DDA were given on days 21
and 42. BALB/c mice develop swelling and redness of one
or more limbs 7–10 days after the second or third injection
with PG in adjuvant [25]. Arthritis was assessed daily, and
inflammation was scored from grade 0 to grade 4 for each
paw [13,36,37]. Female SCID mice of the BALB/c back-
ground (NCI/NCrC.B-17-scid/scid; henceforth BALB/
cSCID) were used for adoptive cell transfer. BALB/cSCID
mice were purchased from the National Cancer Institute
and maintained under germ-free conditions.
Stimulation of lymphocytes in vitro, and adoptive 
transfer of arthritis
To ensure uniformity and reproducibility of disease transfer,
donor spleen cells were isolated from arthritic BALB/c
mice within 1–2 weeks after the onset of inflammation. At
least two paws of donor BALB/c mice were arthritic, and
the cumulative inflammation score (for four paws) was in
the range 5–8. Spleen cells of arthritic BALB/c mice were
collected and cultured in six-well plates (2.5 × 106 cells/ml)
with cartilage PG (50 µg/ml) for 4 days in Dulbecco's mod-
ified Eagle's medium supplemented with 5% fetal bovine
serum (HyClone Laboratories, Logan, Utah, USA). After
stimulation in vitro for 4 days with cartilage PG, non-adher-
ent cells were collected, and live cells (lymphocytes) were
separated on Lympholyte-M (Cedarlane, Ontario, Canada).
Finally, 2 × 107 lymphocytes were injected intraperitoneally
on days 0 and 7 into recipient BALB/cSCID  mice as
described [32].
A standard scoring system used for primary arthritis was
applied to the assessment of disease severity in BALB/
cSCID mice [24,37]. Typically, one to four paws became
inflamed simultaneously 3–5 days after the second cell
transfer, and the rest of the peripheral joints became
inflamed within 2–4 days after the onset of the first symp-
toms. BALB/cSCID mice were scored twice daily, and were
killed as soon as the inflamed paw reached an individual
arthritis score of 2, but not later than 24 hours after the
onset of arthritis. This paw was designated as acute
arthritic (AA), and contralateral or ipsilateral paws that wereAvailable online http://arthritis-research.com/content/7/2/R196
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not inflamed at that time were used as pre-arthritic (PA)
samples. The PA joints did not show evidence of inflamma-
tion on histopathological examination, although thickening
of the synovial lining in small joints was observed occasion-
ally (data not shown). Several arthritic BALB/cSCID mice
were scored daily and were killed 8–10 days after disease
onset. These joint samples represented subacute-chroni-
cally arthritic (CA) samples. In addition to PA, AA and CA
experimental conditions, paws of naive non-immunized
BALB/cSCID mice were used as 'absolutely negative' (con-
trol naive; AN) samples for RNA isolation and subsequent
hybridization. Each sample represented RNA pooled from
four paws of two mice.
Probe preparation
Synthesis and biotinylation of cRNA and hybridization were
performed in accordance with the manufacturer's instruc-
tions (Affymetrix, Santa Clara, California, USA). In brief,
total RNA was isolated from normal or inflamed paws of
mice by using TRIzol reagent (Invitrogen, Gaithersburg,
Maryland, USA) with additional purification on RNeasy col-
umns (Qiagen, Valencia, California, USA). RNA quality was
confirmed by spectrophotometry and electrophoresis on
formaldehyde gels [38]. Double-stranded complementary
DNA was synthesized with the T7-dT24 primer incorporat-
ing a T7 RNA polymerase promoter. Biotinylated cRNA
was prepared with the Enzo BioArray High Yield RNA Tran-
script Labeling Kit (Enzo Diagnostics, Inc., Farmingdale,
New York, USA) and hybridized to the murine genome
Affymetrix U74v2 chip set, which included three DNA
chips, MG_U74Av2, MG_U74Bv2 and MG_U74Cv2,
interrogating more than 36,000 genes that represented
essentially the entire mouse genome [39-42]. Fluorescent
hybridization signals were developed with phycoerythrin-
conjugated streptavidin and were further enhanced with
fluorescently labeled anti-streptavidin antibodies. DNA
chips were scanned to obtain quantitative gene expression
levels. DNA chip hybridization, Fluidics Station operations,
scanning, and preliminary data management were per-
formed in accordance with Affymetrix protocols as
described previously [43,44].
Microarray analysis
Fluorescent intensity data from Affymetrix Microarray Suite
version 5 were exported as CEL files and imported into
DNA-Chip Analyzer version 1.3 [45]. Data were normalized,
and expression values, based on the perfect match/mis-
match (PM/MM) model, were calculated for each DNA
chip. All chips were examined for the image spikes, chip
and gene outliers. Exported expression values for each
DNA chip were combined into a single file (three chips ×
four experimental conditions × three to five replicates), and
imported back to DNA-Chip Analyzer; the resulting data
were normalized by using an array with median probe
intensity.
For the pairwise comparison of experimental conditions,
signals were filtered by using several criteria. Gene expres-
sion was considered above the background if it showed the
signal on most chips (more than 50%; that is, for three rep-
licates, the gene should be detectable on at least two
chips; for five replicates, the gene should be present on at
least three DNA chips). Fold changes for gene expression
were calculated when any of three following criteria were
met: (1) the gene was present in the experimental condition
but absent in the basal condition; (2) the gene was present
in the basal condition but absent in the experimental condi-
tion; (3) the gene was present in both basal condition and
experimental conditions. Student's t-test was used to
determine the statistical significance of the difference in
gene expression between basal and experimental condi-
tions (P < 0.05 was taken as significant). An additional cut-
off threshold of twofold change in gene expression (either
upregulation or downregulation) was used to characterize
a gene as being differentially regulated (for example, a neg-
ative twofold value corresponded to a twofold downregula-
tion). The Fisher exact test (implemented by us in Visual
Basic code for MS Excel 2000) and the Mann–Whitney U-
test (SPSS, Chicago, Illinois, USA) were used to verify non-
paired Student's t-test calculations of the probability of
gene expression differences in pairwise comparisons.
Finally, the false discovery rate was established with 500
permutations for each pairwise comparison to estimate the
proportion of false-positive genes.
To characterize gene expression patterns, hierarchical
gene clustering was performed with a DNA-Chip Analyzer
program [45,46]. The algorithm was based on the distance
between two genes defined as 1 - r, where r is the Pearson
correlation coefficient between the standardized expres-
sion values of the two genes across the samples used. To
characterize functional relationships between differentially
expressed genes, Gene Ontology terms classification [47],
incorporated in DNA-Chip Analyzer, was performed [48].
The significance level for a functional cluster was set at P
< 0.05, and the minimum size of a cluster was three genes.
Venn diagram calculations were performed in Visual Basic
code for MS Excel 2000 to analyze overlapping of sets of
genes differentially expressed in the samples at different
phases of arthritis.
Results
The major goal of the present study was to find and char-
acterize early signature genes whose expressions were dif-
ferent (at least twofold change in the threshold level) and
statistically significant (P  < 0.05) between experimental
groups at different phases of joint inflammation. The induc-
tion of arthritis in BALB/cSCID mice was a multi-step proc-
ess. First, donor BALB/c mice were immunized with
cartilage PG to induce arthritis. Second, spleen cells from
acutely arthritic (AA) donor mice were stimulated in vitroArthritis Research & Therapy    Vol 7 No 2    Adarichev et al.
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with cartilage PG, and live lymphocytes were isolated on a
Lympholyte-M density gradient. Third, these antigen-stimu-
lated donor lymphocytes were injected into BALB/cSCID
mice. For gene expression profiling during the time course
of the adoptively transferred arthritis, RNA was isolated
from pre-arthritic paws (PA) and diseased paws (AA and
CA) (Table 1). In addition, RNA was isolated from normal
paws of naive BALB/cSCID mice and served as a baseline
non-arthritic control condition (AN). Three pairwise com-
parisons were performed: PA versus AN, AA versus AN,
and CA versus AN (hereafter denoted as PA/AN, AA/AN
and CA/AN).
Each experimental condition was reproduced three to five
times (RNA isolation, probe preparation, and independent
hybridizations), and each replicate contained RNA samples
pooled from a total of four paws of two arthritic animals.
When the number of replicates is low and the distribution
of data in the general population is basically unknown, the
applicability of Student's t-test is questionable. We there-
fore analyzed data by using both Student's t-test and the
Fisher exact test, in which the first approach requires nor-
mal data distribution, whereas the second test does not
have this requirement [45,49,50]. Setting the significance
level for the difference between groups at P < 0.05 and no
threshold for the fold change in expression, 1805 genes
passed the Fisher exact test and 1752 genes passed the
DNA-Chip Analyzer Student's t-test [45] for the PA/AN
comparison. In AA/AN pairwise comparisons, 3676 genes
passed the Fisher exact test and 3305 genes passed Stu-
dent's t-test. Concluding that Student's t-test provided sim-
ilar results and was even more conservative than the Fisher
exact test, we employed the former for all further analyses.
Effect of the numbers of replicates on data variability
Being aware of the importance of data reproducibility, we
determined the optimal number of arrays to be included in
experimental design by monitoring the convergence of var-
iance for gene expression signals in five replicates repre-
senting the condition AA. For each replicate, we pooled
equal amounts of quality-controlled RNA samples, isolated
from two inflamed paws of two BALB/cSCID mice that had
been identically treated (in terms of the number of donor
cells and antigen stimulation) and had similar disease onset
and severity. A total of five replicates represented 20 paws
of 10 arthritic mice. We used the coefficient of variation
(CV) to measure data variability. The CV for each gene on
the chip and the mean CV for the entire probe set were cal-
culated. Mean CV reached a plateau when the number of
replicates increased beyond three (Fig. 1, experimental
condition AA) and there was no significant change after-
wards. Therefore, for all other experimental conditions, we
used three replicates representing three independent
hybridization experiments of three RNA samples isolated
from six paws. Mean CV after sampling of the three repeats
ranged between 0.21 and 0.25 for all experimental
conditions.
Arthritis 'signature' genes in pre-inflamed joints
Paws of naive BALB/cSCID mice and still non-inflamed (PA)
paws were clinically normal with no sign of inflammation,
and comparison of these two experimental conditions (PA/
AN) identified a relatively small number of differentially
Table 1
Experimental groups used for adoptive disease transfer and differential expression analysis
Group RNA source Treatment Days after injection No. of animals
AN Naive control (absolute negative) BALB/cSCID paw None N/A 3
PA Normal paw from arthritic BALB/cSCID mouse Cell transfer 6 3
AA Acute arthritic paw of BALB/cSCID mouse Cell transfer 6 5
CA Chronically arthritic paw of BALB/cSCID mouse Cell transfer 12–14 3
Group AN represents naive BALB/cSCID mice that received no cells. Experimental groups PA, AA, and CA received antigen-stimulated 
lymphocytes from arthritic BALB/c donor mice. RNA was isolated from four paws of two mice at the indicated number of days after injection, and 
pooled.
Figure 1
Average coefficient of variation with increasing number of replicates of  gene expression experiments Average coefficient of variation with increasing number of replicates of 
gene expression experiments. Data represent results obtained with 
RNA from normal paws of naive BALB/cSCID mice (AN), clinically normal 
pre-arthritic paws (PA), acutely arthritic paws (AA) and chronically 
inflamed paws (CA).Available online http://arthritis-research.com/content/7/2/R196
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expressed genes. Only 37 of the 36,000 screened genes
were differentially expressed (that is, showed greater than
a ± twofold change relative to threshold level), of which 11
genes were over the ± threefold threshold, and seven
genes changed beyond ± fivefold (Fig. 2). The seven genes
with the most significant change in expression levels
encoded chemokine CC motif receptor 5 (Ccr5), chemok-
ine CXC motif ligand 1 (Cxcl1), interferon-γ-inducible pro-
tein (Ifi47), membrane-spanning 4-domains subfamily A
member 6C (Ms4a6c), tumor necrosis factor-α-induced
protein 6 (Tnfip6), T cell receptor β variable 13 (Tcrbv13),
and Terf1-interacting nuclear factor2 (Tinf2) (Table 2).
Although the upregulation of Tcrbv13, Tgtp and interferon-
induced genes might indicate the appearance of antigen-
specific T cells in the synovium (Table 2), the significant
upregulation of Tnfip6 suggests the activation of an anti-
inflammatory cascade [51]. Thus, gene expression related
to pro-inflammatory and anti-inflammatory events can be
detected even before the migration of inflammatory leuko-
cytes into the joints.
To characterize major biological functions in context with
the initiation phase of the disease, we assigned the 37 early
genes (Table 2, Additional file 1) to separate groups
according to the corresponding protein functions and
Gene Ontology classification [47,48]. We found that differ-
entially expressed genes in PA joints were related to
immune responses, chemokine activity (including chemo-
taxis), cell adhesion, proteolysis regulation, inflammation
and wounding, cytokines, and cytoskeletal activity (Fig. 3,
yellow circles). All clustered genes were upregulated at the
pre-inflamed phase of arthritis.
Gene expression profile in acute and chronic arthritis
To monitor the progression of disease, we analyzed genes
that were differentially expressed in paws with acute and
chronic joint inflammation. Both AA and CA experimental
conditions were associated with the activity of a large
number of genes: 256 genes were upregulated and 21
were downregulated in acute arthritis (AA/AN comparison),
and 201 genes were upregulated and 217 were downreg-
ulated in chronic inflammation (CA/AN) (Fig. 2, Additional
files 2 and 3). A Venn diagram summarizes the relation-
ships between gene sets that were differentially expressed
at different phases of the disease. Only 15 genes were dif-
ferentially expressed in all three phases of the disease (PA,
AA, and CA), 25 genes were differentially expressed both
at the PA phase and during acute inflammation, 127 genes
were active both in acute and chronic phases, and 17 tran-
scripts shared a common expression pattern in pre-
inflamed and chronically inflamed joints (Fig. 2).
Using Gene Ontology terms for the functional classification
of genes differentially expressed in acute and chronic arthri-
tis [47], dozens of cell signaling pathways and gene clus-
ters were identified. By further filtering of functional
clusters, and by combining clusters encoding proteins with
similar functions, we found that the acute and chronic
phases of the disease can be comprehensively described
by the differential expression of 15 macro-clusters (Fig. 3).
Six clusters were found in all three phases of inflammation;
they were related to immune response, chemokine activity,
cytokines, inflammation and wounding, cell adhesion, and
proteolysis regulation. The most abundantly represented
Figure 2
Fold change distribution for genes differentially expressed in pre- inflamed joints, in paws with acute and chronic arthritis, in comparison  with gene expression in normal paws of naive BALB/cSCID mice Fold change distribution for genes differentially expressed in pre-
inflamed joints, in paws with acute and chronic arthritis, in comparison 
with gene expression in normal paws of naive BALB/cSCID mice. Values 
indicate the number of genes that fall in the given range of expression. 
Negative numbers for expression levels indicate downregulation (e.g. a 
negative twofold change corresponds to downregulation to 0.5-fold). 
Spikes at ± 5-fold expression change represent the extremes of histo-
gram when combining all genes with differential expression level 
greater than ± 5-fold. The Venn diagram (bottom) indicates the number 
of overlapping genes that were differentially expressed in pre-inflamed 
and arthritic joints.Arthritis Research & Therapy    Vol 7 No 2    Adarichev et al.
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Table 2
Array-based expression values of upregulated or downregulated genes in pre-inflamed joint
Affy ID Description Gene Mean AN 
expression
AN presence 
call
Mean PA 
expression
PA presence 
call
Fold Cluster
161968_f_at Chemokine (CC motif) receptor 5 Ccr5 1 A 57.1 P 57.1 D
95349_g_at Chemokine (CXC motif) ligand 1 Cxcl1 1 A 55.9 P 55.9 D
104750_at Interferon-γ inducible protein Ifi47 0.69 A 15.69 P 22.7 D
130509_at Membrane-spanning 4-domains member A6C Ms4a6c 1.17 A 10.27 P 8.78 D
93106_i_at T-cell receptor beta, variable 13 Tcrbv13 1.86 A 10.34 P 5.55 A
98474_r_at Tumor necrosis factor-α induced protein 6 Tnfaip6 3.61 A 19.97 P 5.54 D
94761_at Chemokine (CC motif) ligand 7 Ccl7 24.47 A 115.33 P 4.71 D
101578_f_at Actin, β, cytoplasmic Actg 188.33 P 859.16 P 4.56 A
102736_at Chemokine (CC motif) ligand 2 Ccl2 29.89 P 125.48 P 4.20 D
95121_at Polymerase (DNA-directed) ε 4 p12 Pole4 8.95 P 26.13 P 2.92 C
93397_at Chemokine (CC) receptor 2 Ccr2 93.67 P 259.21 P 2.77 D
102906_at T cell-specific GTPase Tgtp 24.27 A 66.03 P 2.72 D
97322_at Membrane-spanning 4-domains member A6B Ms4a6b 9.43 A 25.16 P 2.67 D
93514_at Myosin, light polypeptide 3 Myl3 29.28 A 77.42 P 2.64 A
103089_at CD48 antigen Cd48 34.17 A 85.82 P 2.51 C
103507_at EGF-like hormone receptor-like sequence 1 Emr1 59.04 A 145.95 P 2.47 D
96764_at Interferon-inducible GTPase Ifigtp 66.38 A 157.88 P 2.38 D
102326_at Neutrophil cytosolic factor 2 Ncf2 23.67 P 55.88 P 2.36 D
104388_at Chemokine (CC motif) ligand 9 Ccl9 246.56 P 568.47 P 2.31 D
93321_at Interferon-activated gene 203 Ifi203 43.58 P 99.27 P 2.28 C
94085_at Proteoglycan, secretory granule Prg 329.68 P 747.2 P 2.27 D
92762_at C-type lectin, superfamily member 6 Clecsf6 35.73 A 80.64 P 2.26 D
93136_at Dermatan sulphate proteoglycan 3 Dspg3 30.23 A 67.77 P 2.24 B
101753_s_at P lysozyme structural Lzps 635.78 P 1398.72 P 2.20 D
94939_at CD53 antigen Cd53 112.16 P 243.17 P 2.17 D
94958_at RIKEN cDNA 1110013L07 gene 1110013L07Rik 24.91 A 53.7 P 2.16 A
162066_f_at Rho interacting protein 3 Rip3 19.15 A 40.54 P 2.12 A
93039_at RIKEN cDNA 1190003P12 gene 1190003P12Rik 36.44 P 77.03 P 2.11 A
101048_at Protein tyrosine phosphatase, receptor type, C Ptprc 138.7 A 289.19 P 2.09 D
92217_s_at Glycoprotein 49 B Gp49b 72.11 P 148.01 P 2.05 D
93869_s_at Hematopoietic-specific A1-d protein Bcl2a1a 49.43 A 100.11 P 2.03 D
103989_at RIKEN cDNA 4432417F03 gene 4432417F03Rik 35.66 A 72.18 P 2.02 B
160611_at Cytochrome P450 polypeptide 4v3 Cyp4v3 82 P 164.59 P 2.01 B
162107_r_at Tissue inhibitor of metalloproteinase 1 Timp1 9.64 P 4.39 A -2.20 E
164493_i_at Makorin, ring finger protein, 1 Mkrn1 8.23 P 3.21 A -2.56 F
167637_i_at RIKEN cDNA 4833424O15 gene 4833424O15Rik 8.19 P 2.64 A -3.11 F
167950_r_at Terf1 (TRF1)-interacting nuclear factor 2 Tinf2 8.82 P 1.65 P -5.35 E
Affy ID, unique Affymetrix probe set identifier. Description, gene description. Gene, gene abbreviation. Mean AN expression, average expression value in basal 
experimental condition of clinically normal paws of naive severe combined immunodeficient mice without cell transfer. Mean PA expression, average expression value in 
pre-arthritic joints. Presence call, average presence call for gene in AN or PA experimental condition: P, transcript was actually present in the majority of samples; A, 
transcript was actually absent in the majority of samples. Fold, fold change in gene expression in PA joint compared with AN basal expression. Cluster, cluster 
designation from Fig. 5. Difference in expression was significant by Mann–Whitney U-test, P < 0.05. Differential expression for listed genes was either greater than 
twofold overexpression or less than twofold downregulation (negative values). Genes that were differentially expressed in both pre-inflamed paws and in vitro-stimulated 
lymphocytes used for cell transfer are shown in bold type.Available online http://arthritis-research.com/content/7/2/R196
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genes in inflamed joints were those involved in immune
responses: 51 genes in AA and 25 genes in CA. These
genes were upregulated as much as 31-fold (group aver-
age) in acute arthritis and 15-fold in chronic arthritis (Fig.
3). Cytokine and chemokine genes demonstrated the high-
est overexpression levels: about 64-fold in acute and 28-
fold in chronic arthritis, where both groups included more
than a dozen genes. Proteolysis-regulating genes (pro-
teases and their inhibitors) were highly represented at the
acute phase (45 genes), but were less abundant in chronic
arthritis (19 genes). Extracellular matrix-related genes,
mostly relevant to tissue repair and healing, were more
abundant in chronic than acute disease. Some functional
clusters were phase-specific, such as lysosome, antigen
presentation, scavenger receptors, immunoglobulin bind-
ing, and complement cascade; these genes were preferen-
tially expressed in acute joint inflammation. Suppression of
genes related to the respiratory chain complex was specific
to chronic inflammation (Fig. 3).
Hierarchical clustering of arthritis phase-specific genes
To identify genes whose expression might be specific for
the actual phase of arthritis, and to combine transcripts by
the pattern of their expression through all disease phases,
we applied a hierarchical clustering technique [46]. Genes
that were specific for pairwise comparisons (PA/AN, AA/
AN, and CA/AN) were combined into one single file
(excluding redundant genes); the merged set included 507
genes. Hierarchical clustering was performed for all exper-
imental conditions studied (AN, PA, AA, and CA), and four
major gene clusters were identified, each with a distinct
expression pattern (Fig. 4, clusters I–IV). Using further clas-
sification analysis with Gene Ontology terms, to examine
the functions of genes inside each cluster, we identified
genes encoding proteins whose biological functions were
the most relevant to arthritis development and progression.
Cluster I contained genes with major functions in collagen
turnover and tissue repair; the expression of these genes
reached a peak in chronically inflamed joints.
Cluster II was the largest cluster including about half of all
phase-specific genes (Fig. 4). The cluster included genes
with roles in immune, inflammatory and stress responses,
extracellular matrix formation, cell growth, and receptor
activity. The expression of cluster II genes reached a peak
at the acute phase of joint inflammation.
Transcription of genes in clusters III and IV gradually
decreased during disease progression (Fig. 4). These
genes were mostly related to cytoskeleton remodeling, the
formation of cell junctions, and the production of structural
molecules such as desmin, β-3 laminin, envoplakin, and
dystonin (for a detailed gene list see Additional files 1, 2, 3).
Genes associated with early arthritis (Table 2) were found
Figure 3
Gene activities at different phases of arthritis progression Gene activities at different phases of arthritis progression. All clusters 
identified in pre-inflamed joints (PA/AN comparison, yellow circles), 
acute arthritis (AA/AN, red circles), and chronic arthritic paws (CA/AN, 
blue circles) are indicated by the number of genes in the cluster (circle 
diameter represents cluster size) and the average fold change of gene 
expression (logarithmic horizontal scale). The size of the cluster varies 
from 3 genes ('complement cascade' cluster) in pre-inflamed joints to 
51 genes ('immune response' cluster) in acute arthritis. AN, normal 
paws of naive BALB/cSCID mice; PA, clinically normal pre-arthritic paws; 
AA, acutely arthritic paws; CA, chronically inflamed paws.Arthritis Research & Therapy    Vol 7 No 2    Adarichev et al.
R203
in clusters III and IV, further underlining the importance of
cell adhesion and cytoskeleton remodeling during the initi-
ation phase of arthritis.
Expression patterns of early arthritis genes
Hierarchical clustering of a large number of phase-specific
genes (n = 507) (Fig. 4) obscured the expression pattern
of a relatively small number (n = 37) of early arthritis genes
(Table 2). A separate hierarchical clustering was therefore
performed for these 37 early genes, and the levels of
expression were monitored at later phases of the disease.
Six distinct expression patterns were identified (Fig. 5, clus-
ters A–F) using this approach. Clusters A–D contained
early arthritis genes whose transcription increased as the
disease progressed, reaching a peak in the pre-inflamed
joint or during inflammation. Cluster A included genes that
coded for variable parts of the T cell receptor, together with
genes related to cytoskeleton reorganization such as Rho
interacting protein 3, myosin, and β-actin (reviewed in
[52,53]). Cluster A genes were at the peak of their expres-
sion in the PA joint. However, most early arthritis genes in
clusters C and D showed an expression peak later, at the
acute phase of inflammation (Fig. 5), and encoded chemok-
ine receptors (Ccr2  and  Ccr5) and chemokine ligands
(Cxcl1,  Ccl2,  Ccl7, and Ccl9). Clusters C and D also
included interferon-activating genes Ifi203, Ifi47, and Ifigtp,
and cell differentiation antigens such as CD48 and CD53.
Hierarchical clusters E and F contained four genes whose
expression was downregulated in the pre-inflamed joint but
returned to a 'normal' level (as expressed in naive paws)
during arthritis progression. Clusters E and F included
genes encoding Terf1-interacting nuclear factor 2, tissue
inhibitor of metalloproteinase 1, makorin, and DNA clone
4833424O15 with unknown function (Table 2 and Fig. 5).
Discussion
This study describes genome-wide gene activity taking
place in mouse joints during three major phases of autoim-
mune arthritis: initiation, acute inflammation, and chronic
inflammation. Spleen cells from PG-immunized arthritic
BALB/c mice were used to transfer the disease into non-
immunized syngeneic SCID mice [30,32]. This adoptive
transfer system minimized the individual differences that
are typical in primary arthritis (induced by systemic immuni-
zation), and also excluded antigen-independent stimulation
of the immune system by the adjuvant. Additional benefits
of the cell transfer included a decrease in the time needed
for arthritis development, and uniformity and synchroniza-
tion of joint inflammation in recipient mice [32].
Two major criteria were used to select genes that might be
important for arthritis development: (1) significant differ-
ences in expression levels between experimental groups
and (2) the fold change in expression levels. When only the
first criterion was applied, genome-wide analysis identified
a large number of genes whose expression was signifi-
cantly (P < 0.05) different between any pair of the experi-
mental conditions compared. Irrespective of the statistics
used (either unpaired Student's t-test, the Fisher exact test
or the Mann–Whitney U-test), the number of differentially
expressed genes was found to represent about 5–10% of
the entire mouse genome. We further 'filtered' these genes
by using a cut-off threshold set at twofold change of
expression, because this threshold could reflect a physio-
logically important change in gene activity, and a twofold
change exceeded the average CV for all pairwise compari-
sons. Decreasing the number of 'false positive' genes by
application of these two filtering procedures proved to be
an effective technique for the identification of genes that
are likely to be involved in arthritis development.
The present study indicates that the number of differentially
expressed genes increases with the progression of the dis-
ease. At the initiation phase, when no clinical symptoms of
inflammation were yet detected, only 37 genes were upreg-
Figure 4
Signature gene clusters at different phases of autoimmune arthritis Signature gene clusters at different phases of autoimmune arthritis. 
Hierarchical clustering was performed for genes whose expression sig-
nificantly differed when paws of naive mice (AN) were compared with 
those in the pre-arthritic (PA), acute (AA), or chronic (CA) phases of 
arthritis. The total number of genes (n = 507) is less than the sum of the 
phase-specific genes because of partial overlap (Fig. 2). Rows repre-
sent individual genes; columns represent individual expression values 
for each gene at the indicated phase of arthritis. The major biological 
activities, specific for each cluster, were examined by using functional 
clustering of genes. This analysis yielded four different expression pat-
terns (clusters I–IV). Upregulated genes are shown in red, downregu-
lated genes in blue.Available online http://arthritis-research.com/content/7/2/R196
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ulated or downregulated. However, a differential expres-
sion of 277 genes was observed at the acute phase, and
chronic inflammation was characterized by the differential
activity of 418 genes. Interestingly, most early arthritis sig-
nature genes (27 of 37) remained upregulated or downreg-
ulated in inflamed joints (Fig. 2). A different set of genes
was also involved in acute inflammation. At the chronic
phase, less than half of AA-specific genes (127 of 277)
were differentially expressed, and another half was CA-spe-
cific. A very limited number of transcripts (n = 15) remained
upregulated or downregulated in all three phases of
arthritis.
Activated T cells must be present in the peripheral blood of
recipient BALB/cSCID mice after the transfer, but donor lym-
phocytes can be detected in joints as early as 3–5 days
after the second transfer [32]. In earlier studies [31], and in
control experiments (data not shown), using fluorescein-
labeled or isotope-labeled donor lymphocytes, only very
few cells were found in joints during the first week of
transfer, and a second cell transfer was needed to induce
a significant influx of lymphocytes into the joints and cause
subsequent inflammation. In this study, we detected over-
expression of a T cell-specific GTPase (Tgtp) and T cell
receptor  β ( Tcrbv13) in still non-inflamed (pre-arthritic)
paws of recipient BALB/cSCID mice as early as 3–5 days
after the second injection, indicating the presence of donor
BALB/c lymphocytes. Thus, the initiation and development
of arthritis in adoptively transferred PGIA must depend on
cooperation between adaptive immunity cells (represented
by donor BALB/c lymphocytes) and cells of innate
immunity (represented by non-lymphoid cells in the recipi-
Figure 5
Hierarchical clustering (left) and expression patterns (A–F) for 37 early arthritis genes (listed in Table 2) differentially expressed in pre-inflamed (PA)  joints of recipient BALB/cSCID mice Hierarchical clustering (left) and expression patterns (A–F) for 37 early arthritis genes (listed in Table 2) differentially expressed in pre-inflamed (PA) 
joints of recipient BALB/cSCID mice. Gene expression was compared with normal paws (AN) of naive BALB/cSCID mice (PA/AN comparison, with a 
cut-off threshold at twofold change). The expression profiles of these 37 signature genes are shown for each phase of the disease (PA, acute [AA], 
or chronic [CA]) and also in normal paws.Arthritis Research & Therapy    Vol 7 No 2    Adarichev et al.
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ent BALB/cSCID mice). Analysis of the cellular and tissue
specificity of gene expression, using public gene expres-
sion databases [54-56], indicated that genes encoding
CD48 (Cd48), membrane-spanning 4A6B and 4A6C
(Ms4a6b and Ms4a6c), epidermal growth factor-like recep-
tor-like protein 1 (Emr1), and interferon-induced 47 kDa
protein (Ifi47) were most probably originating from donor
lymphoid cells, whereas other early arthritis genes (Table 2)
were related to the activation of the innate immune system
(represented by macrophages, dendritic cells, and cells of
myeloid lineage) of recipient BALB/cSCID mice.
Transcriptional control of gene activity is only one compo-
nent of the complex cellular regulatory pathways. In other
words, the functional activity of a protein depends on sev-
eral factors such as interaction with other proteins, phos-
phorylation/dephosphorylation, subcellular
compartmentalization, and other post-translational modifi-
cations. All of these factors might be involved in the regula-
tion of interactions between the donor lymphocytes and the
synovial/joint cells of recipient mice that lack an adaptive
immune system. The list of genes we present in this study
is rather short; that is, it includes only genes profoundly
affected during arthritis initiation and progression at the
level of transcription. Genes and proteins that are under
subtle regulatory pressure, or are controlled by non-genetic
mechanisms such as protein phosphorylation and other
post-translational events, could not be detected and ana-
lyzed in this study. The development of new proteomics
assays, and the synthesis of existing knowledge in cellular
signaling pathways with information provided by gene
expression studies, will be necessary to build up a com-
plete arthritis-related regulatory network and to unravel the
mechanisms involved in the development and progression
of autoimmune arthritis.
Conclusions
The development and progression of a complex polygenic
autoimmune disease such as RA are controlled by hun-
dreds or thousands of genes, in addition to the MHC.
Despite the relatively high incidence of RA in the human
population, only a few studies have applied gene array
methods to the monitoring of disease progression and effi-
cacy of treatment, or to predicting the prognosis of the dis-
ease. The major obstacles in the human studies are the
relatively late diagnosis of RA, the large variety of cell types
(cells of the immune system and of synovial joints) involved
in autoimmune arthritic processes, and the extreme genetic
heterogeneity of the human population. The present study
applied an adoptively transferred murine model of RA and
a microarray approach to detect differentially expressed,
disease-related signature genes in PA (still non-inflamed)
joints, days before the clinical symptoms or histopathologi-
cal abnormalities of joint inflammation could be observed.
However, the detection of early arthritis signature genes in
joints can be done only in an experimental system in which
particular joints have already been affected before the
inflammatory symptoms can be identified. To make this
experimental system uniform, that is, to exclude individual
variations, we adoptively transferred antigen (PG)-specific
lymphocytes (representing cells of adaptive immunity) from
primarily arthritic mice into syngeneic SCID mice, which
lack an adaptive immune system. In this highly synchro-
nized and uniform system we were able to detect differen-
tially expressed genes in still non-inflamed paws of arthritis-
'prone' animals. We identified a relatively small number of
mostly upregulated early arthritis signature genes (known
to be involved in arthritic processes and/or autoimmunity),
some of which were expressed at even higher levels in the
acute phase of arthritis. These early arthritis signature
genes, originating from donor cells, indicated the involve-
ment of adaptive immunity, whereas the innate immunity
genes were differentially expressed by cells of the
recipients.
The early signature genes, together with those that were
differentially expressed in the acute (277 genes) and
chronic (418 genes) phase of arthritis, are listed in the
Additional files. Although many of these differentially
expressed genes, detected either in the acute phase or
during the progression of the disease, have been impli-
cated in inflammation or autoimmunity, the list contains a
significant number of differentially expressed genes whose
function, or association with arthritis, is unknown at
present.
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